168 related articles for article (PubMed ID: 35304977)
1. P-Glycoprotein and Breast Cancer Resistance Protein Transporter Inhibition by Cyclosporine and Quinidine on the Pharmacokinetics of Oral Rimegepant in Healthy Subjects.
Bhardwaj R; Collins JL; Stringfellow J; Madonia J; Anderson MS; Finley JA; Stock DA; Coric V; Croop R; Bertz R
Clin Pharmacol Drug Dev; 2022 Jul; 11(7):889-897. PubMed ID: 35304977
[TBL] [Abstract][Full Text] [Related]
2. Bioequivalence of rimegepant, a small molecule CGRP receptor antagonist, administered as an oral tablet, a sublingual orally disintegrating tablet, and a supralingual orally disintegrating tablet: two phase 1 randomized studies in healthy adults.
Croop R; Bhardwaj R; Anderson MS; Matschke KT; Hould J; Bertz R; Liu J; Lipton RB
Cephalalgia; 2024 Feb; 44(2):3331024231219505. PubMed ID: 38366390
[TBL] [Abstract][Full Text] [Related]
3. Rimegepant Orally Disintegrating Tablet for Acute Migraine Treatment: A Review.
DeFalco AP; Lazim R; Cope NE
Ann Pharmacother; 2021 May; 55(5):650-657. PubMed ID: 32909437
[TBL] [Abstract][Full Text] [Related]
4. The Pharmacokinetics, Safety, and Tolerability of Rimegepant 75 mg Are Similar in Elderly and Nonelderly Adults: A Phase 1, Open-Label, Parallel-Group, Single-Dose Study.
Bhardwaj R; Morris B; Bertz R; Croop R; Liu J
Clin Pharmacol Drug Dev; 2024 Jan; 13(1):37-44. PubMed ID: 37904724
[TBL] [Abstract][Full Text] [Related]
5. Clinical Drug-Drug Interaction Studies to Evaluate the Effects of a P-Glycoprotein Inhibitor, CYP3A Inhibitors, and a CYP3A Inducer on the Pharmacokinetics of Naldemedine in Healthy Subjects.
Fukumura K; Kawaguchi N; Ishibashi T; Kubota R; Tada Y; Ogura E
Clin Drug Investig; 2020 Jun; 40(6):529-540. PubMed ID: 32323104
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of CYP2D6 by quinidine and its effects on the metabolism of cilostazol.
Bramer SL; Suri A
Clin Pharmacokinet; 1999; 37 Suppl 2():41-51. PubMed ID: 10702886
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of drug-drug interaction of lusutrombopag, a thrombopoietin receptor agonist, via metabolic enzymes and transporters.
Katsube T; Inoue Y; Fukuhara T; Kano T; Wajima T
Eur J Clin Pharmacol; 2020 Dec; 76(12):1659-1665. PubMed ID: 32666123
[TBL] [Abstract][Full Text] [Related]
8. Rimegepant 75 mg in Subjects With Hepatic Impairment: Results of a Phase 1, Open-Label, Single-Dose, Parallel-Group Study.
Bhardwaj R; Ivans A; Stringfellow J; Morris B; Coric V; Croop R; Bertz R
Clin Pharmacol Drug Dev; 2023 Aug; 12(8):790-800. PubMed ID: 37073443
[TBL] [Abstract][Full Text] [Related]
9. Effect of Daridorexant on the Pharmacokinetics of P-Glycoprotein Substrate Dabigatran Etexilate and Breast Cancer Resistance Protein Substrate Rosuvastatin in Healthy Subjects.
Anliker-Ort M; Dingemanse J; Janů L; Kaufmann P
Clin Drug Investig; 2023 Nov; 43(11):827-837. PubMed ID: 37858005
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and Safety of Single and Multiple Daily Dosing of 75-mg Rimegepant Orally Disintegrating Tablets in Healthy Chinese Adults: A Randomized Placebo-Controlled Trial.
Li Y; Wang X; Ballesteros-Perez A; Bertz R; Lu Z
Clin Pharmacol Drug Dev; 2023 Jun; 12(6):594-601. PubMed ID: 36808268
[TBL] [Abstract][Full Text] [Related]
11. Investigation of the Effect of Lasmiditan on the Pharmacokinetics of P-Glycoprotein and Breast Cancer Resistance Protein Substrates.
Luffer-Atlas D; Wilbraham D; Posada MM; Landry J; Tsai M; Pearlman EM
J Clin Pharmacol; 2024 Jan; 64(1):94-102. PubMed ID: 37566903
[TBL] [Abstract][Full Text] [Related]
12. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
Berman G; Croop R; Kudrow D; Halverson P; Lovegren M; Thiry AC; Conway CM; Coric V; Lipton RB
Headache; 2020 Sep; 60(8):1734-1742. PubMed ID: 32799325
[TBL] [Abstract][Full Text] [Related]
13. Effect of cyclosporine coadministration on the pharmacokinetics of eltrombopag in healthy volunteers.
Aslanis V; Zhang J; Lomeli B; Grosch K; Ouatas T
Cancer Chemother Pharmacol; 2018 Nov; 82(5):847-855. PubMed ID: 30171280
[TBL] [Abstract][Full Text] [Related]
14. Cyclosporine markedly raises the plasma concentrations of repaglinide.
Kajosaari LI; Niemi M; Neuvonen M; Laitila J; Neuvonen PJ; Backman JT
Clin Pharmacol Ther; 2005 Oct; 78(4):388-99. PubMed ID: 16198658
[TBL] [Abstract][Full Text] [Related]
15. A Study of the Effect of Cyclosporine on Fevipiprant Pharmacokinetics and its Absolute Bioavailability Using an Intravenous Microdose Approach.
Weiss HM; Umehara KI; Erpenbeck VJ; Cain M; Vemula J; Elbast W; Zollinger M
Drug Metab Dispos; 2020 Oct; 48(10):917-924. PubMed ID: 32739890
[TBL] [Abstract][Full Text] [Related]
16. A Drug-Drug Interaction Study to Evaluate the Impact of Rimegepant on OCT2- and MATE1-Mediated Transport of Metformin in Healthy Participants.
Bhardwaj R; Morris B; Matschke K; Bertz R; Croop R; Liu J
Clin Pharmacol Drug Dev; 2024 May; 13(5):465-473. PubMed ID: 38174905
[TBL] [Abstract][Full Text] [Related]
17. A placebo-controlled, randomized, single and multiple dose study to evaluate the safety, tolerability, and pharmacokinetics of rimegepant in healthy participants.
Bertz R; Bhardwaj R; Morris BA; Ashbrenner E; Coric V; Croop R
Cephalalgia; 2023 Jun; 43(6):3331024231179131. PubMed ID: 37282507
[TBL] [Abstract][Full Text] [Related]
18. Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor.
Mendell J; Zahir H; Matsushima N; Noveck R; Lee F; Chen S; Zhang G; Shi M
Am J Cardiovasc Drugs; 2013 Oct; 13(5):331-42. PubMed ID: 23784266
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the effect of P-glycoprotein inhibition and induction on talazoparib disposition in patients with advanced solid tumours.
Elmeliegy M; Láng I; Smolyarchuk EA; Chung CH; Plotka A; Shi H; Wang D
Br J Clin Pharmacol; 2020 Apr; 86(4):771-778. PubMed ID: 31770456
[TBL] [Abstract][Full Text] [Related]
20. Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine.
Parasrampuria DA; Mendell J; Shi M; Matsushima N; Zahir H; Truitt K
Br J Clin Pharmacol; 2016 Dec; 82(6):1591-1600. PubMed ID: 27530188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
